Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance...

por Ställberg, Björn, Naya, Ian, Ekelund, Jan, Eckerwall, Göran
Publicado 2015

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis

por Naya, Ian P., Tombs, Lee, Lipson, David A., Compton, Chris
Publicado 2018

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis

por Naya, Ian, Tombs, Lee, Lipson, David A., Boucot, Isabelle, Compton, Chris
Publicado 2019

Long-term outcomes following first short-term clinically important deterioration in COPD

por Naya, Ian P., Tombs, Lee, Muellerova, Hana, Compton, Christopher, Jones, Paul W.
Publicado 2018

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD

por Sion, Katya Y. J., Huisman, Eline L., Punekar, Yogesh S., Naya, Ian, Ismaila, Afisi S.
Publicado 2017

Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis

por Punekar, Yogesh Suresh, Sharma, Sheetal, Pahwa, Ankit, Takyar, Jitender, Naya, Ian, Jones, Paul W.
Publicado 2017

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective

por Shah, Dhvani, Driessen, Maurice, Risebrough, Nancy, Baker, Timothy, Naya, Ian, Briggs, Andrew, Ismaila, Afisi S.
Publicado 2018

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

por Singh, Dave, Maleki-Yazdi, M Reza, Tombs, Lee, Iqbal, Ahmar, Fahy, William A, Naya, Ian
Publicado 2016

Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials

por Maleki-Yazdi, M. Reza, Singh, Dave, Anzueto, Antonio, Tombs, Lee, Fahy, William A., Naya, Ian
Publicado 2016

Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials

por Ray, Riju, Tombs, Lee, Asmus, Michael J., Boucot, Isabelle, Lipson, David A., Compton, Chris, Naya, Ian
Publicado 2018

Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study

por Paly, Victoria Federico, Naya, Ian, Gunsoy, Necdet B, Driessen, Maurice T, Risebrough, Nancy, Briggs, Andrew, Ismaila, Afisi S
Publicado 2019

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of...

por Buhl, Roland, Kuna, Piotr, Peters, Matthew J, Andersson, Tomas LG, Naya, Ian P, Peterson, Stefan, Rabe, Klaus F
Publicado 2012

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

por Alcázar Navarrete, Bernardino, Boucot, Isabelle, Naya, Ian, Tombs, Lee, Lipson, David A., Compton, Chris, Sousa, Ana R., Feldman, Gregory
Publicado 2018

Measuring disease activity in COPD: is clinically important deterioration the answer?

por Singh, Dave, Criner, Gerard J., Naya, Ian, Jones, Paul W., Tombs, Lee, Lipson, David A., Han, MeiLan K.
Publicado 2020

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?

por Singh, Dave, Criner, Gerard J., Naya, Ian, Jones, Paul W., Tombs, Lee, Lipson, David A., Han, MeiLan K.
Publicado 2021

Preventing clinically important deterioration with single-inhaler triple therapy in COPD

por Naya, Ian, Compton, Chris, Ismaila, Afisi S., Birk, Ruby, Brealey, Noushin, Tabberer, Maggie, Zhu, Chang-Qing, Lipson, David A., Criner, Gerard
Publicado 2018

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study

por Feldman, Gregory J., Sousa, Ana R., Lipson, David A., Tombs, Lee, Barnes, Neil, Riley, John H., Patel, Sadhana, Naya, Ian, Compton, Chris, Alcázar Navarrete, Bernardino
Publicado 2017

Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial

por Kerwin, Edward M, Boucot, Isabelle H, Vogelmeier, Claus F, Maltais, Francois, Naya, Ian P, Tombs, Lee, Jones, Paul W, Lipson, David A, Keeley, Tom, Bjermer, Leif
Publicado 2020

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement

por Vogelmeier, Claus F, Naya, Ian P, Maltais, François, Bjermer, Leif, Kerwin, Edward M, Tombs, Lee, Jones, Paul W, Compton, Chris, Lipson, David A, Boucot, Isabelle H
Publicado 2021

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

por Bjermer, Leif, Boucot, Isabelle H, Maltais, François, Kerwin, Edward M, Naya, Ian P, Tombs, Lee, Jones, Paul W, Compton, Chris, Lipson, David A, Vogelmeier, Claus F
Publicado 2021